![]() |
About Lifespan Technologies |
|
Michael Mostert |
Lifespan Technologies was founded in 1992 to develop medical diagnostic and assay products. Lifespan has acquired exclusive rights to a novel new heparin binding protein. This technology has potential applications for:
Clinical Diagnostics
- Therapeutic drug monitoring
- Heparin clearance: Determination of
whether patients are at risk of
heparinization
- Determining predisposition of patients
to heparin induced
thrombocytopenia.
|